Vineet Punia, MD
Neurology · Cleveland Heights, OHNPI 1205154754
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 70.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $15,788 and has fallen 73.6% since, to $4,174 in 2025.
Across 71 payments — averaging $584.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$29K
- Catalyst Pharmaceuticals, Inc.$7K
- UCB, Inc.$4K
- SK Life Science, Inc.$673
- Jazz Pharmaceuticals Inc.$338
- Greenwich Biosciences, Inc.$31
Across 17 payments — averaging $10,809 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$170K
- Catalyst Pharmaceuticals, Inc.$14K
- UCB SA$52
What the payments were for
- Consulting fees$14,26834%
- Speaking & faculty fees$4,00010%
- Travel & lodging$19,59547%
- Food & beverage$2,8727%
- Education$7552%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 40 | $29,321 |
| Catalyst Pharmaceuticals, Inc. | 5 | $6,928 |
| UCB, Inc. | 14 | $4,198 |
| SK Life Science, Inc. | 7 | $673 |
| Jazz Pharmaceuticals Inc. | 3 | $338 |
| Greenwich Biosciences, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,489 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 122 | $7,451 |
| Lacosamide | 35 | $3,952 |
| Oxcarbazepine | 31 | $3,358 |
| Lamotrigine | 105 | $3,314 |
| Clobazam | 27 | $2,219 |
| Zonisamide | 41 | $2,082 |
| Topiramate | 27 | $749 |
| Gabapentin | 27 | $723 |
| Clonazepam | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland Heights
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.